BC Week In Review | Mar 3, 2017
Company News

Auris, King's College London deal

Auris and King’s College London extended into early 2018 a 2015 deal to discover and develop small molecules for Auris’ AM-102 project. Auris said it expects to select a lead compound for the program by...
BC Week In Review | Nov 16, 2015
Company News

Auris Medical, King’s College London deal

Auris and King’s College London partnered to discover and develop small molecules for Auris’ AM-102 project. AM-102 compounds bind to an undisclosed target to treat tinnitus. King’s college will lead discovery and optimization, and Auris...
BioCentury | Nov 13, 2006
Emerging Company Profile

Amira: Beyond Singulair

Based on the work of CSO Peppi Prasit, Amira Pharmaceuticals Inc. is developing compounds to treat inflammation, including one that inhibits multiple targets in the leukotriene pathway to treat asthma. Prasit believes the compound, AM-103,...
Items per page:
1 - 3 of 3